Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin in cigarette smokers

Circulation

Volumn 112, Issue 7, 2005, Pages 1024-1029

  McAdam, Brendan F ^a   Byrne, Daniel ^a   Morrow, Jason D ^a   Oates, John A ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Drugs; Inflammation; Platelets; Smoking; Thromboxane

Indexed keywords

11 OXOTHROMBOXANE B2; 6 OXOPROSTAGLANDIN F1 ALPHA; CREATININE; CYCLOOXYGENASE 2; PROSTACYCLIN; ROFECOXIB; THROMBOXANE A2;

ADULT; ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; ICOSANOID METABOLISM; INFLAMMATORY CELL; MALE; METABOLITE; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; URINALYSIS; URINARY EXCRETION;

ADULT; CROSS-OVER STUDIES; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; EPOPROSTENOL; HUMANS; LACTONES; MALE; MEMBRANE PROTEINS; PLATELET ACTIVATION; PROSTAGLANDINS; REFERENCE VALUES; SMOKING; SULFONES; THROMBOXANE A2;

EID: 23844442838     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.542696     Document Type: Article

References (50)

1. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation. 2000;102:840-845.
2. 2. Science. 2002;296:539-541.
3. Hennan JK, Huang J, Barrett TD, Driscoll EM, Willens DE, Park AM, Crofford LJ, Lucchesi BR. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation. 2001;104:820-825.
4. Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, Marnett LJ, Morrow JD, Fazio S, Linton MF. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation. 2002;105:1816-1823.
5. Pratico D, Tillmann C, Zhang ZB, Li H, FitzGerald GA. Acceleration of atherogenesisby COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci U S A. 2001;98:3358-3363.
6. Crofford LJ, Oates JC, McCune WJ, Gupta S, Kaplan MJ, Catella-Lawson F. Morrow JD, McDonagh KT, Schmaier AH. Thrombosis in patients with connective tissue diseases treated with specific COX-2 inhibitors: a report of four cases. Arthritis Rheum. 2000;43:1891-1896.
7. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz M, Hawkey CJ, Hochberg MC. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR study group. N Engl J Med. 2000;343:1520-1528.
8. Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, Gertz BJ. Cardiovascular thrombotic events in controlled, clinical trials of Rofecoxib. Circulation. 2001;104:2280-2288.
9. Merck press release. Merck Announces Voluntary Worldwide Withdrawal of VIOXX®. September 30, 2004. Available at: http://www.vioxx.com/rofecoxib/ vioxx/consumer/index.jsp. Accessed September, 2004.
10. McAdam BF, Catella-Lawson F, Mardini I, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX): the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A. 1999;96:272-277.
11. McAdam BF, Catella-Lawson F, Morrison BW, Kapoor S, Kugubu DA, Antes L, Lasseter KC, Quan H, Gertz BJ, FitzGerald GA. Effects of specific inhibition of COX-2 on sodium balance, hemodynamics and vasoactive eicosanoids. J Pharmacol Exp Ther. 1999;289:735-741.
12. Weksler BB, Tack-Goldman K, Subramanian VA, Gay WA. Cumulative inhibitory effect of low-dose aspirin on vascular prostacyclin and platelet thromboxane production in patients with atherosclerosis. Circulation. 1985;71:332-340.
13. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med. 1986;315:983-989.
14. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ. 2002;324:71-86.
15. Nowak J, Murray JJ, Oates JA, FitzGerald GA. Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation. 1987;76:6-14.
16. Bazzano LA, He J, Muntner P, Vupputuri S, Whelton PK. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med. 2003;138:891-897.
17. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982;69:1366-1372.
18. FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ, Lawson JA, Brash AR. Endogenous biosynthesis of prostacyclin, thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983;71:676-688.
19. 2 by GC/MS. J Chromatogr. 1993;612:179-185.
20. 1α by gas chromatography-mass spectrometry. J Chromatogr Biomed Appl. 1994;653:117-122.
21. Tone Y, Inoue H, Hara S, Yokoyama C, Hatae T, Oida H, Narumiya S, Shigemoto R, Yukawa S, Tanabe T. The regional distribution and cellular localization of mRNA encoding rat prostacyclin synthase. Eur J Cell Biol. 1997;72:268-277.
22. Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, Sugimoto Y, Ichikawa A, Aze Y, Tanaka T, Yoshida N. Altered pain perception and inflammatory response in mice lacking the IP receptor. Nature. 1997;388:678-682.
23. Smyth EM, FitzGerald GA. Human prostacyclin receptor. Vitam Horm. 2002;65:149-165.
24. Nakagawa O, Tanaka I, Usui T, Harada M, Sasaki Y, Itoh H, Yoshimasa T, Namba T, Narumiya S, Nakao K. Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system. Circulation. 1994;90:1643-1647.
25. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976;263:663-665.
26. 2 and prostacyclin elevate cyclic AMP levels in elicited populations of mouse peritoneal macrophages. Adv Prostaglandin Thromboxane Res. 1980;8:1691-1693.
27. Eisenhut T, Sinha B, Grottrup-Wolfers E, Semmler J, Siess W, Endres S. Prostacyclin analogs suppress the synthesis of tumor necrosis factor-alpha in LPS-stimulated human peripheral blood mononuclear cells. Immunopharmacology. 1993;26:259-264.
28. Cullen L, Kelly L, Connor SO, Fitzgerald DJ. Selective cyclooxygenase-2 inhibition by nimesulide in man. J Pharmacol Exp Ther. 1998;287:578-582.
29. Rocca B, Secchiero P, Ciabattoni G, Ranelletti FO, Catani L, Guidotti L, Melloni E, Maggiano N, Zauli G, Patrono C. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A. 2002;99:7634-7639.
30. Morley J, Bray MA, Jones RW, Nugteren DH, van Dorp DA. Prostaglandin and thromboxane production by human and guinea-pig macrophages and leucocytes. Prostaglandins. 1979;17:729-746.
31. Pawlowski N, Kaplan G, Harmill AL, Cohn ZA, Scott WA. Arachidonic acid metabolism by human monocytes: studies with platelet-depleted cultures. J Exp Med. 1983;158:393-412.
32. MacDermot J, Kelsey CR, Waddell KA, Richmond R, Knight RK, Cole PJ, Dollery CT, Landon DN, Blair IA. Synthesis of leukotriene B4, and prostanoids by human alveolar macrophages: analysis by gas chromatography/mass spectrometry. Prostaglandins. 1984;27:163-179.
33. Sebaldt RJ, Shelter JR, Oates JA, Roberts LJ, FitzGerald GA. Inhibition of eicosanoid biosynthesis by glucocorticoids in humans. Proc Natl Acad Sci U S A. 1990;87:6974-6978.
34. O'Sullivan MG, Huggins EM, Meade EA, DeWitt DL, McCall CE. Lipopolysaccharide induces COX-2 in alveolar macrophages. Biochem Biophys Res Commun. 1992;187:1123-1127.
35. Nusing R, Sauter G, Fehr P, Durmuller U, Kasper M, Gudat F, Ullrich V. Localization of thromboxane synthase in human tissues by monoclonal antibody Tu 300. Pathol Anat Histopathol. 1992;421:249-254.
36. Karim S, Habib A, Levy-Toledano S, Maclouf J. Cyclooxygenase-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J Biol Chem. 1996;271:12042-12048.
37. Danesh J, Muir J, Wong YK, Ward M, Gallimore JR, Pepys MB. Risk factors for coronary heart disease and acute-phase proteins: a population-based study. Eur Heart J. 1999;20:954-959.
38. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
39. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med. 2002;347:5-12.
40. Ridker PM. Role of inflammatory biomarkers in prediction of coronary heart disease. Lancet. 2001;358:946-948.
41. Baker CSR, Hall RJC, Evans TJ, Pomerance A, Maclouf J, Creminon C, Yacoub MH, Polak JM. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol. 1999;19:646-655.
42. Schonbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol. 1999;155:1281-1291.
43. 2-dependent plaque instability. Circulation. 2001;104:921-927.
44. 2? Circulation. 2002;105:1620-1622.
45. 2 stimulates vascular smooth muscle hypertrophy by up-regulating the synthesis and release of endogenous basic fibroblast growth factor. J Biol Chem. 1993;268:17397-17403.
46. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650-1655.
47. Cipollone F, Patrignani P, Greco A, Panara MR, Padovano R, Cuccurullo F, Patrono C, Rebuzzi AG, Liuzzo G, Quaranta G, Maseri A. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation. 1997;96:1109-1116.
48. Hart RG, Leonard AD, Talbert RL, Pearce LA, Cornell E, Bovill E, Feinberg WM. Aspirin dosage and thromboxane synthesis in patients with vascular disease. Pharmacotherapy. 2003;23:579-584.
49. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1993;268:6610-6614.
50. Bhattacharyya DK, Lecomte M, Dunn J, Morgans DJ, Smith WL. Selective inhibition of prostaglandin endoperoxide synthase-1 (cyclooxygenase-1) by valerylsalicylic acid. Arch Biochem Biophys. 1995;317:19-24.